Savara Inc (NASDAQ:SVRA) Shares Purchased by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. raised its holdings in Savara Inc (NASDAQ:SVRA) by 54.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 690,609 shares of the company’s stock after purchasing an additional 242,249 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.42% of Savara worth $2,928,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in SVRA. Jennison Associates LLC boosted its stake in Savara by 17.5% during the 3rd quarter. Jennison Associates LLC now owns 6,732,776 shares of the company’s stock valued at $28,547,000 after acquiring an additional 1,001,296 shares during the last quarter. LMR Partners LLP raised its stake in shares of Savara by 138.3% in the 3rd quarter. LMR Partners LLP now owns 36,800 shares of the company’s stock valued at $156,000 after purchasing an additional 132,900 shares in the last quarter. Oppenheimer & Co. Inc. grew its stake in Savara by 14.8% in the third quarter. Oppenheimer & Co. Inc. now owns 115,604 shares of the company’s stock worth $490,000 after purchasing an additional 14,867 shares in the last quarter. Victory Capital Management Inc. increased its holdings in Savara by 7.0% in the third quarter. Victory Capital Management Inc. now owns 140,010 shares of the company’s stock valued at $594,000 after buying an additional 9,180 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in Savara by 95.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 31,658 shares of the company’s stock valued at $134,000 after buying an additional 15,423 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. JMP Securities reiterated a “market outperform” rating and issued a $9.00 price target on shares of Savara in a report on Tuesday, October 1st. Evercore ISI reiterated an “in-line” rating and set a $5.00 target price (down previously from $7.00) on shares of Savara in a research note on Wednesday, November 13th. Finally, HC Wainwright reduced their price target on shares of Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.17.

Savara Stock Performance

SVRA stock opened at $3.36 on Monday. Savara Inc has a 1 year low of $2.82 and a 1 year high of $5.70. The stock has a market capitalization of $576.64 million, a price-to-earnings ratio of -7.81 and a beta of 1.02. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The stock’s fifty day moving average is $3.76 and its two-hundred day moving average is $4.12.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.11). On average, research analysts predict that Savara Inc will post -0.45 EPS for the current year.

Insider Activity

In other Savara news, Director Joseph S. Mccracken purchased 20,000 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was bought at an average price of $2.95 per share, with a total value of $59,000.00. Following the completion of the purchase, the director now owns 210,837 shares in the company, valued at $621,969.15. This trade represents a 10.48 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 5.13% of the company’s stock.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.